Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Sep;21(5):746-755.
doi: 10.1016/j.jmoldx.2019.04.003. Epub 2019 May 8.

Recommendations for Clinical CYP2C9 Genotyping Allele Selection: A Joint Recommendation of the Association for Molecular Pathology and College of American Pathologists

Victoria M Pratt  1 , Larisa H Cavallari  2 , Andria L Del Tredici  3 , Houda Hachad  4 , Yuan Ji  5 , Ann M Moyer  6 , Stuart A Scott  7 , Michelle Whirl-Carrillo  8 , Karen E Weck  9
Affiliations
Review

Recommendations for Clinical CYP2C9 Genotyping Allele Selection: A Joint Recommendation of the Association for Molecular Pathology and College of American Pathologists

Victoria M Pratt et al. J Mol Diagn. 2019 Sep.

Abstract

The goals of the Association for Molecular Pathology Pharmacogenomics (PGx) Working Group of the Association for Molecular Pathology Clinical Practice Committee are to define the key attributes of PGx alleles recommended for clinical testing and a minimum set of variants that should be included in clinical PGx genotyping assays. This document provides recommendations for a minimum panel of variant alleles (Tier 1) and an extended panel of variant alleles (Tier 2) that will aid clinical laboratories when designing assays for CYP2C9 testing. The Working Group considered the functional impact of the variants, allele frequencies in different populations and ethnicities, the availability of reference materials, and other technical considerations for PGx testing when developing these recommendations. Our goal is to promote standardization of testing PGx genes and alleles across clinical laboratories. These recommendations are not to be interpreted as restrictive but to provide a reference guide. The current document will focus on CYP2C9 testing that can be applied to all CYP2C9-related medications. A separate recommendation on warfarin PGx testing is being developed to include recommendations on CYP2C9 alleles and additional warfarin sensitivity-associated genes and alleles.

PubMed Disclaimer

References

    1. Relling M. Clinical implementation of pharmacogenetics: CPIC guidelines. Clin Chem Lab Med. 2015;53:S75.
    1. Moyer A.M., Rohrer Vitek C.R., Giri J., Caraballo P.J. Challenges in Ordering and Interpreting Pharmacogenomic Tests in Clinical Practice. Am J Med. 2017;130:1342–1344. - PubMed
    1. Wu A.H.B. Genotype and phenotype concordance for pharmacogenetic tests through proficiency survey testing. Arch Pathol Lab Med. 2013;137:1232–1236. - PubMed
    1. Pratt V.M., Everts R.E., Aggarwal P., Beyer B.N., Broeckel U., Epstein-Baak R., Hujsak P., Kornreich R., Liao J., Lorier R., Scott S.A., Smith C.H., Toji L.H., Turner A., Kalman L.V. Characterization of 137 Genomic DNA Reference Materials for 28 Pharmacogenetic Genes: a GeT-RM Collaborative Project. J Mol Diagn. 2016;18:109–123. - PMC - PubMed
    1. Scott S.A., Jaremko M., Lubitz S.A., Kornreich R., Halperin J.L., Desnick R.J. CYP2C9*8 is prevalent among African-Americans: implications for pharmacogenetic dosing. Pharmacogenomics. 2009;10:1243–1255. - PMC - PubMed

Publication types